DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Van Loon, J. A.
Right arrow Articles by Weinshilboum, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Loon, J. A.
Right arrow Articles by Weinshilboum, R. M.

Thiopurine methyltransferase isozymes in human renal tissue

JA Van Loon and RM Weinshilboum

Department of Pharmacology, Mayo Clinic/Mayo Foundation, Rochester, MN 55905.

Thiopurine methyltransferase (TPMT) catalyzes the S-methylation of thiopurine drugs such as 6-mercaptopurine (6-MP). Levels of TPMT activity in human tissue are controlled by a common genetic polymorphism. On a genetic basis, 88.6% of humans have high, 11.1% have intermediate, and 0.3% have very low or undetectable levels of enzyme activity. Ion exchange chromatography of a pooled human kidney preparation yielded two peaks of TPMT activity. Approximately 83-88% of the enzyme activity eluted as a major peak (peak I), while 12-17% eluted in a distinct second peak (peak II). Each of these isozymes was then purified further by gel filtration chromatography. The two isozymes had similar pH optima, similar KM values for the reaction co- substrates, 6-MP and S-adenosyl-L-methionine, and similar Ki and Ks values for the TPMT inhibitor 3,4-dimethoxy-5-hydroxybenzoic acid. Electrophoretic mobilities of the two isozymes were identical, and both had molecular weights of approximately 30,000. To determine whether tissue from individual subjects with different presumed genotypes for the TPMT genetic polymorphism contained one, the other, or both isozymes, TPMT activities were measured in renal preparations from 48 patients. Of these patients, 40 (83%) had high and 8 (16%) had intermediate levels of activity. Ion exchange chromatography of renal preparations from three individuals with intermediate and three individuals with high TPMT activities showed that all six samples contained both isozymes in similar proportions. Our results demonstrate that two isozymes of TPMT are present in the human kidney.(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 18, Issue 5, pp. 632-638, 09/01/1990
Copyright © 1990 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
C. V. Preuss, T. C. Wood, C. L. Szumlanski, R. B. Raftogianis, D. M. Otterness, B. Girard, M. C. Scott, and R. M. Weinshilboum
Human Histamine N-Methyltransferase Pharmacogenetics: Common Genetic Polymorphisms that Alter Activity
Mol. Pharmacol., April 1, 1998; 53(4): 708 - 717.
[Abstract] [Full Text]

Home page
 Pharmacol. Rev.Home page
J. W. Lohr, G. R. Willsky, and M. A. Acara
Renal Drug Metabolism
Pharmacol. Rev., March 1, 1998; 50(1): 107 - 142.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1990 by the American Society for Pharmacology and Experimental Therapeutics.